Keerthi Shetty, Phd, Mba Email and Phone Number

• Serve as strategic thought partner with Program Team Lead; oversaw company's first IND filing• Facilitate Program Leadership Team meetings; lead cross-functional program teams to deliver key milestones and communicate program updates, risks, and mitigations to sub-teams and Leadership• Develop goals and execute program strategy in line with needs of Functional Leads, Program Leadership Team, and Corporate Strategy; frequently present strategic and operational dashboard updates and proposals to Governance and Executive Leadership Team; heavily involved with Global Development Plan, Integrated Development Plan, long-range planning, and strategic program review• Recipient of company’s Annual Values Award for ability to explore novel solutions

• Briefed Executive Director of Business Development on partnering meetings for 2020 JPM Healthcare conference as well as Sachs Immuno-oncology Innovation forum and identified promising opportunities• Perform deep-dive of entire tech portfolio to assess the commercial potential of DFCI assets • Build IP portfolios for investigators; Collated data on DFCI start-ups (IPOs, M&As) for Board meetings• Assisted in the review of final proposals for DFCI's first Pipeline Accelerator Program to assist PIs in forming NewCos

• Managed a new venture providing single-cell and TCR sequencing, antigen prediction, and immunoassay services• Implemented annual budget/business plan, achieving goal of institutional independence by 2021• Identified new and maintained existing academic and industry clients; facilitated weekly calls and/or emails to ensure projects were delivered on time and the appropriate analysis for their patient cell types were utilized

• Oversaw a portfolio of 6 cutting-edge neoantigen pre-clinical/Phase I FiH vaccine trials and molecular research studies across 6 indications in a lean, fast paced, matrixed environment• Lead cross-functional communication with clinicians, scientific leads, computational biologists, legal/finance teams, regulatory affairs, and external stakeholders to drive vaccine development• Established Center for Personal Cancer Vaccines with support from CEO and CSO; built vein-to-veininfrastructure (LIMS), short and long-term strategy, and team (made key hires, including a direct report)• Served as thought partner to Director/IND sponsor on evaluating options and driving decisions, defining and achieving milestones, solving challenges with tight deadlines, and identifying opportunities to scale• Identified, negotiated, and established partnerships with a bioinformatics CRO with machine learningexpertise as well as a CDMO to serve our complex manufacturing needs, resulting in program relaunch after a 2-year hiatus (before I joined) and reduction in vein-to-vein lead time & costs by 30%• Continuously mapped the competitive landscape, identified areas where we can be the leaders, and determine how to scale and sustain the clinical and scientific operations• Hands-on strategic management: short/long-term strategy planning and implementation; prepared presentations for senior leadership; lead scientific and clinical operations team meetings; facilitated internal and external communications; negotiated terms with CROs; collaborated with the Broad Institute for genomics sequencing and analysis• Built and maintained tools to optimize processes and improve efficiency: worked closely with Information Systems teams to build and launch DFCI's first LIMS to efficiently track clinical samples as well as to automate our artificial intelligence-based bioinformatics workflow

• Foster investor and entrepreneur relations, source potential deals based on NSV's investment thesis, and perform due diligence via data analysis and phone conversations with lead investors/KOLs• Utilize Pitchbook to assess startup's competitive landscape, opportunities for exit strategy, and team/board members

• Managed projects with scientists and policy experts to explore how the public can better adapt toinnovation; prepared for and facilitated governance and steering committee meetings• Facilitated roundtable discussions with startup CEOs, the FDA, economists, ethicists, and physicians onthe regulation of neuro-enhancement devices, resulting in a white paper on recommended guidelines• Co-wrote testimony for Senate Committee hearing on recommendations for maximizing basic researchROI: signed into law by President Obama as the American Innovation and Competitiveness Act in Jan '17• Co-led development and launch of Public Face of Science, a multi-year data initiative on the public-science nexus: built and maintained strong relations with KOLs as well as the Directors of the Sloan, RitaAllen, and Gordon & Betty Moore Foundations for funding and strategic purposes

Winter 2017 session: worked in a 6-person team to determine commercial viability and devising regulatory strategy of a local startup’s novel medical device; estimated $1.5B potential annual revenue in US market (20% market penetrance); recommended entering EU market.Summer 2016 session: worked with a 9-person team to perform a competitive analysis of fast casual restaurants within the greater Boston area for both in-store dining and catering services. I specifically worked on comparing the companies' marketing, branding and customer engagement activities via online platforms. The client had a positive response and plans to re-evaluate their strategy targeting certain demographics via online marketing, which is its primary method of advertising. • Solved complex problems through a hypothesis-based approach• Conducted interviews with relevant stakeholders and performed secondary research to drive critical insights• Created and utilized analytic tools (e.g., forecast models) to support key decision-making• Communicated recommendations to clients to inform strategy and maximize value

• Selected as seminar instructor, head of capstone project groups, and residential adviser for the Science, Policy, and Innovation session• Developed curriculum and syllabus for courses that I taught on topics such as genetic engineering, personalized medicine, and synthetic biology• Served as mentor and incorporator for a capstone group's startup on vaccine education in Southeast Asia

Laboratory of David Schatz, Dept. of Immunobiology, Yale UniversityProject title: RAG1 and RAG2 interactions with recombination centers during V(D)J recombinationDescription: Used chromatin immunoprecipitation (ChIP)-qPCR to analyze the mechanism of RAG interactions with RSSs during V(D)J recombination. Familiar with NGS technology, ChIP-seq and RNA-seq protocols, Molecular Cloning, Western Blotting, Flow Cytometry, and navigating the UCSC Genome Browser.•Analyzed quantitative data to determine the recruitment dynamics of immune system proteins and to calculate the number of these molecules per cell•Completed Computational Biology Summer Course•Supervised an undergraduate student on his senior thesis•Led department career development/pathways seminar•Served as Graduate Teaching Assistant -Created curriculum and facilitated weekly discussion sections for Human Biology, a course for non- science majors -Developed a new lesson plan for a Genetics course taught at local middle schools through the Science Education Outreach Program

Launched by former Secretary of State Hillary Clinton, the VSFS is an eInternship program that enables college and graduate students to engage with the department’s ongoing diplomatic efforts. I worked with the Indonesia S&T team to develop a virtual communications hub between Indonesian and American scientists.

Project title: High-throughput Real-time PCR: reducing it to practiceDescription: Tested the combination of new reagents and equipment (Roche Lysis Buffer, Echo 555 with Omics Software, and Roche Light Cycler 1536) to help develop a new high throughput screening assay for endogenous gene expression analysis.Streamlined the workflow and automation processes to help develop a novel high throughput screening assay for drug discovery via endogenous gene expression that would reduce reagent cost by 20%; results presented at the 2011 Society for Laboratory Automation and Screening MeetingResults presented at the 2011 Society for Laboratory Automation and Screening (formerly SBS) meeting.

Thesis project title: RNA-Mediated reprogramming of DNA rearrangement in Oxytricha trifallaxProject description: Demonstrated the ability of a non-coding RNA template to reprogram the genetic arrangement in progeny ciliate cells.•Performed PCR, molecular cloning, extensive genome alignments •Completed course on computational biology

Project title: Identification and characterization of hemocyte-specific genes in the A. gambiaeDescription: Used RNAi silencing and immunofluorescence microscopy to preliminarily characterize a hemocyte-specific gene in the malaria vector A. gambiae as possibly being involved in the organism’s immune response as many malaria parasites survived in the absence of this gene.